Sort
30,917 grants matching “tumor microenvironment”
EGR2 in T cell tolerance
$327,850Thomas F Gajewski · University Of Chicago · R01 · FY2012 · CA
Host STING pathway in anti-tumor immunity
$327,850Thomas F Gajewski · University Of Chicago · R01 · FY2014 · CA
Metabolic changes in ovarian cancer cells initiated by metastasis to adipose tiss
$327,850Ernst Lengyel · University Of Chicago · R01 · FY2016 · CA
EGR2 in T cell tolerance
$327,850Thomas F Gajewski · University Of Chicago · R01 · FY2016 · CA
Host STING pathway in anti-tumor immunity
$327,850Thomas F Gajewski · University Of Chicago · R01 · FY2015 · CA
Cyclic Dinucleotides in Combinatorial Immunotherapy for Cancer
$327,850Young J. Kim · Vanderbilt University Medical Center · R01 · FY2017 · CA
Metabolic changes in ovarian cancer cells initiated by metastasis to adipose tiss
$327,850Ernst Lengyel · University Of Chicago · R01 · FY2013 · CA
Host STING pathway in anti-tumor immunity
$327,850Thomas F Gajewski · University Of Chicago · R01 · FY2016 · CA
EGR2 in T cell tolerance
$327,850Thomas F Gajewski · University Of Chicago · R01 · FY2015 · CA
Metabolic changes in ovarian cancer cells initiated by metastasis to adipose tiss
$327,850Ernst Lengyel · University Of Chicago · R01 · FY2017 · CA
Enzyme-instructed self-assembly for anticancer nanomedicine
$327,850Bing Xu · Brandeis University · R01 · FY2010 · CA
Kinetic analysis of Myc-induced carcinogenesis in vivo
$327,831Gerard Ian Evan · University Of California, San Francisco · R01 · FY2012 · CA
Project 3: Developing CAR T Cell Therapies to Target Tumor Heterogeneity in Advanced Prostate Cancer
$327,804Owen N Witte · University Of California Los Angeles · P50 · FY2023 · CA
Project 3: Developing CAR T Cell Therapies to Target Tumor Heterogeneity in Advanced Prostate Cancer
$327,804Owen N Witte · University Of California Los Angeles · P50 · FY2021 · CA
Modeling Therapy of Disseminated Cancer Cells in Bone Marrow (PQ 17)
$327,803Gary D Luker · University Of Michigan At Ann Arbor · R01 · FY2015 · CA
The role of platelets in tumor growth, wound healing and other angiogenesis disea
$327,793Giannoula Lakka Klement · Genesys Research Institute, Inc. · R01 · FY2010 · GM
Functional Tissue Factor on Activated Endothelium
$327,750Massachusetts General Hospital · R01 · FY2001 · HL
Myeloid Suppressor Cell-Mediated Immune Suppression of Tumor Specific T Cells
$327,742Shu-Hsia Chen · Icahn School Of Medicine At Mount Sinai · R01 · FY2013 · CA
Core 1: Mathematical Core
$327,719Alexander Robertson Allan Anderson · H. Lee Moffitt Cancer Ctr & Res Inst · U54 · FY2025 · CA
Role of miR-105 in breast cancer metastasis
$327,684Shizhen Emily Wang · Beckman Research Institute/City Of Hope · R01 · FY2013 · CA
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumor
$327,684Behnam Badie · Beckman Research Institute/City Of Hope · R01 · FY2013 · CA
Combining targeted radionuclide therapy with a localized in situ vaccine to overcome immune suppression in the tumor microenvironment and augment T cell responses
$327,645Paul M Sondel · University Of Wisconsin-Madison · P01 · FY2021 · CA
Molecular mechanism by which Tim-3 induces T cell dysfunction and inhibits anti-t
$327,637Vijay K Kuchroo · Brigham And Women'S Hospital · P01 · FY2015 · AI
Identification of small molecule inhibitors of USP18
$327,632Anton Simeonov · National Center For Advancing Translational Sciences · ZIA · FY2024 · TR
Project 1: Combine Viro-Immunotherapy and Natural Killer Cells for the Treatment of Gliomas
$327,626Juan Fueyo · University Of Tx Md Anderson Can Ctr · P50 · FY2025 · CA